ENVISAGENICS
Envisagenics focus on the discovery of RNA therapeutics. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial intelligence. Over 30 million people in the US suffer from genetic diseases or cancer that could be caused by mutations affecting RNA splicing. 370 human diseases are known to be caused by splicing errors, and more remain to be discovered. Their breakthrough technolo... gy, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery from RNA-seq data, using Artificial Intelligence. We are using our software to identify splicing errors causative of diseases, identify the right drug targets, and develop RNA therapeutics through partnerships and collaborations with Biopharma. Their in-silico RNA therapeutics discovery platform replaces expensive drug-target selection and lead design with efficient computer simulations, decreasing time, cost, and failure risk of drug development programs. Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory.
ENVISAGENICS
Industry:
Artificial Intelligence Bioinformatics Biotechnology Machine Learning Therapeutics
Founded:
2014-04-22
Address:
New York, New York, United States
Country:
United States
Website Url:
http://www.envisagenics.com
Total Employee:
11+
Status:
Active
Contact:
(516)847-5485
Email Addresses:
[email protected]
Total Funding:
27.06 M USD
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default Google Font API Google Analytics Apple Mobile Web Clips Icon Google Tag Manager WordPress Wordpress Plugins
Current Advisors List
Current Employees Featured
Founder
Investors List
National Cancer Institute
National Cancer Institute investment in Grant - Envisagenics
M12 - Microsoft's Venture Fund
M12 - Microsoft's Venture Fund investment in Series A - Envisagenics
New York Ventures
New York Ventures investment in Series A - Envisagenics
Madrona Venture Group
Madrona Venture Group investment in Series A - Envisagenics
Third Kind Venture Capital
Third Kind Venture Capital investment in Series A - Envisagenics
Dynamk Capital
Dynamk Capital investment in Series A - Envisagenics
Red Cell Partners
Red Cell Partners investment in Series A - Envisagenics
National Cancer Institute
National Cancer Institute investment in Grant - Envisagenics
National Institutes of Health
National Institutes of Health investment in Grant - Envisagenics
Madrona Venture Group
Madrona Venture Group investment in Seed Round - Envisagenics
Official Site Inspections
http://www.envisagenics.com
- Host name: 104.21.52.45
- IP address: 104.21.52.45
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Envisagenics"
Envisagenics - LinkedIn
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic ... See details»
Envisagenics - Crunchbase Company Profile
Envisagenics reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions. See details»
Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic ...
Jun 5, 2024 Founded in 2014 as a spin-out from Cold Spring Harbor Laboratory, Envisagenics is a woman- and minority-led organization, with several grants from esteemed institutions like the … See details»
Envisagenics, Inc. Company Profile | New York, NY | Competitors ...
Find company research, competitor information, contact details & financial data for Envisagenics, Inc. of New York, NY. Get the latest business insights from Dun & Bradstreet. See details»
Envisagenics - Craft
Envisagenics has 5 employees across 2 locations and $3.08 m in total funding,. See insights on Envisagenics including office locations, competitors, revenue, financials, executives, … See details»
Envisagenics - The Org
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Their mission is to reduce the complexity of biomedical data to accelerate the development of innovative … See details»
Envisagenics - VentureRadar
Envisagenics' breakthrough technology, SpliceCore, is a cloud-based platform that is experimentally validated to predict drug targets and biomarkers through splicing discovery … See details»
Envisagenics, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Jun 10, 2025 Founded in 2014 as a spin-out from Cold Spring Harbor Laboratory, Envisagenics is a woman- and minority-led organization, with several grants from esteemed institutions like … See details»
Envisagenics - New York City, USA - bionity.com
Envisagenics was founded in 2014 as a spinout of Cold Spring Harbor Laboratory. Our mission is to reduce the complexity of biomedical data to accelerate the development of innovative … See details»
Envisagenics - Red Cell Partners
Envisagenics is on a mission to reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions through RNA splicing analytics and artificial … See details»
ENVISAGENICS
Envisagenics is dedicated to turning scientific innovation into life-changing therapies through the power of collaboration. Please connect to explore what’s possible. See details»
Envisagenics - Funding, Financials, Valuation & Investors
Jun 4, 2024 Envisagenics has raised a total of $52.1M in funding over 14 rounds. Their latest funding was raised on Jun 4, 2024 from a Series B round. Which funding types raised the … See details»
Envisagenics - zoonop.com
Overview Envisagenics is a biotechnology company focused on the discovery and development of novel RNA splicing therapeutics using artificial intelligence (AI). Founded as a spinout from … See details»
Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic ...
Founded in 2014 as a spin-out from Cold Spring Harbor Laboratory, Envisagenics is a woman- and minority-led organization, with several grants from esteemed institutions like the National … See details»
Envisagenics - Contacts, Employees, Board Members, Advisors
Envisagenics reduce the complexity of biomedical data to accelerate the development of innovative therapeutic solutions. See details»
Envisagenics Raises Series B to Fuel AI-Enabled Novel Therapeutic ...
Jun 5, 2024 Envisagenics, an AI-driven revenue generating biotechnology company focused on discovery and development of novel RNA splicing therapeutics, today announced a Series B … See details»
ENVISAGENICS
At Envisagenics, we’re changing that. By focusing on disease-specific splicing events that are also common across patients, we’re uncovering an entirely new class of drug targets, enabling … See details»
Former Departmental CSO of Eli Lilly Joins Envisagenics Board of ...
New York, NY (July 16, 2024) – Envisagenics, an AI-driven RNA splicing therapeutics company, today announced the appointment of Kalpana Merchant, Ph.D. to its Board of Directors. Dr. … See details»
Agentic AI will revolutionize business in the cognitive era
2 days ago Agentic AI is revolutionizing business and could lead to a hybrid workforce, but policy-makers and society must ensure that it is developed responsibly. See details»
ENVISAGENICS
RNA Therapeutics DevelopmentWe are advancing a growing pipeline of novel and prevalent therapeutic targets across oncology, neurodegeneration, and other high-need indications, with … See details»